Quality‐of‐life outcomes in patients with advanced melanoma: A review of the literature
Open Access
- 1 January 2017
- journal article
- review article
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 30 (6) , 511-520
Abstract
Summary: For patients with metastatic melanoma, the emergence of immune checkpoint inhibitors and targeted BRAF and MEK inhibitors has markedly enhanced clinical outcomes compared with chemotherapy. However, these novel agents are also associated with unique sets of adverse events, and increased overall survival can lead to prolonged exposure to some novel agents. Therefore, clinical evaluation of these therapies has now included the analysis of health‐related quality of life (HRQoL) in addition to more traditional efficacy and safety outcomes as a measure of patient perception of benefit. The current review focuses on HRQoL outcomes in clinical trials of immune checkpoint inhibitors and targeted therapies in patients with advanced and metastatic melanoma to inform healthcare providers about patient perception of HRQoL as a new perspective in treatment decision making.Keywords
Funding Information
- Novartis Pharmaceuticals Corporation
This publication has 51 references indexed in Scilit:
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trialThe Lancet Oncology, 2016
- Recommendations for Incorporating Patient-Reported Outcomes Into Clinical Comparative Effectiveness Research in Adult OncologyJournal of Clinical Oncology, 2012
- Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanomaActa Oncologica, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Evaluating Minimal Important Differences for the FACT-Melanoma Quality of Life QuestionnaireValue in Health, 2009
- Psychological distress surrounding diagnosis of malignant and nonmalignant skin lesions at a pigmented lesion clinicJournal of Plastic, Reconstructive & Aesthetic Surgery, 2006
- Psychosocial Predictors of Survival in Metastatic MelanomaJournal of Clinical Oncology, 1999
- Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.Journal of Clinical Oncology, 1997
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993
- Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanomaEuropean Journal of Cancer, 1993